fratricide-resistant
Wugen Nabs $115M for Pivotal Study of Allogeneic CAR-T
Wugen; CAR-T; allogeneic; off-the-shelf therapy; fratricide-resistant; funding; pivotal trial; T-cell malignancies
Actionable Insights Powered by AI
Wugen; CAR-T; allogeneic; off-the-shelf therapy; fratricide-resistant; funding; pivotal trial; T-cell malignancies